TOKYO - Japanese pharmaceutical giant Shionogi & Co. said Thursday it will establish a research hub in April with Chiba University Hospital to work on the development of a nasal spray vaccine to be used against COVID-19 and other respiratory infections.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
